Merus Presents Preclinical Data Demonstrating Efficacy Of Zeno In Cancer Models With High NRG1 Expression At The AACR Annual Meeting 2024
Portfolio Pulse from Benzinga Newsdesk
Merus N.V. (NASDAQ:MRUS) presented preclinical data at the AACR Annual Meeting 2024 showing the efficacy of zenocutuzumab (Zeno) in cancer models with high NRG1 expression. The study demonstrated Zeno's anti-tumor activity across multiple tumor types, including significant tumor growth inhibition in 7 out of 28 patient-derived xenograft models. Zeno, a HER2 × HER3 bispecific antibody, also inhibited proliferation in specific gastric and breast cancer cell lines, as well as an NRG1-amplified lung cancer cell line.
April 08, 2024 | 4:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merus N.V. presented promising preclinical data on Zeno's efficacy in cancer models with high NRG1 expression, indicating potential for future clinical applications.
The presentation of positive preclinical data on Zeno by Merus at a prestigious conference like AACR enhances the company's scientific credibility and could positively influence investor perception. This data, demonstrating significant anti-tumor activity in various cancer models, suggests potential for future clinical success, which could drive investor interest and potentially impact the stock price positively in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100